Presentations Highlight Results of Clinical Data for MLN8237 and VELCADE(R) in ... MarketWatch (press release) Also presented were biomarker data from a phase 3 study comparing VELCADE(R) (bortezomib) and rituximab (VcR) to rituximab (R) alone in patients with relapsed or refractory follicular lymphoma (FL). These data were presented during oral presentations ... |
